ResearchMoz

Computational Biology (Pharmacodynamics, Cellular Modeling, Computational Genomics, Proteomics, Pharmacogenomics, Pharmacokinetics, Human Simulation Software, Drug Discovery & Development) Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2012 - 2018

Transparency Market Research
Published Date » 2013-05-07
No. Of Pages » 112
   
 The computational biology market is predicted to have a notable growth owing to its wide use by biotechnology and pharmaceutical companies to reduce the incidences of late stage failures of their drugs and to thereby curb R&D expenditure. Computational biology is also assisting in reducing the extensive use of humans in trials and is therefore useful for pediatric trials, trials on pregnant women and orphan disease research. 
   
 This report analyses the global market for computational biology by two main types of studies-cellular modeling and disease modeling. Each of these segments has been further analyzed by various studies with use of simulation, right from drug discovery to drug development. The market has also been bifurcated on the basis of tools which include...
Table of Content

Chapter 1 Introduction
1.1 Report Description
1.2 Market Segmentation
1.3 Scope Of The Report
1.4 Research Methodology
1.4.1 Sources
1.4.1.1 Secondary Research
1.4.1.2 Primary Research
1.4.1.3 Models
1.5 Assumptions

Chapter 2 Executive Summary
2.1 Market Snapshot: Global Computational Biology Market (2011 & 2018)
2.2 Global Computational Biology Market, by Types, 2011 (USD Million)

Chapter 3 Global Computational Biology Market Dynamics
3.1 Market Overview
3.2 Drivers
3.2.1 Failure Of Drug Candidates in Late Stage of Clinical Trials
3.2.1.1 Average Cost to Develop One New Drug (1975 -2011) (USD Million)
3.2.1.2 Trend of Rise in Failure of Phase II Clinical Trials (2006- 2012)
3.2.1.3 Reasons For Failure (%) in Phase II & Phase III
3.2.2 Enhanced Computational Tools
3.2.3 Improved Government Funding &Industrial Support
3.3 Restraints
3.3.1 Lack of Standardization
3.3.2 Non-Verified Predictive Models
3.4 Challenges
3.4.1 Shortage of Skilled Resources
3.4.2 Data Storage
3.5 Opportunities
3.5.1 Cloud Computing
3.5.2 Modelling And Simulations in Paediatrics Drug Development
3.6 Porters Five Forces Analysis
3.6.1 Bargaining Power of Suppliers
3.6.2 Bargaining Power of Buyers
3.6.3 Threat of New Entrants
3.6.4 Threat Of Substitutes
3.6.5 Competitive Rivalry
3.7 Market Attractiveness Analysis
3.7.1 Market Attractiveness Analysis: Global Computational Biology Market, by Geography
3.8 End User Analysis
3.8.1 End User Analysis: Global Computational Biology Market, 2011 & 2018 (%)

Chapter 4 Global Computational Biology Market, by Applications
4.1 Introduction
4.1.1 Cellular Modelling and Simulation
4.1.1.1 Computational Genomics
4.1.1.1.1 Global Computational Genomics Market Revenues, 2010 – 2018 (USD Million)
4.1.1.2 Computational Proteomics
4.1.1.2.1 Global Computational Proteomics Market Revenues, 2010 – 2018 (USD Million)
4.1.1.3 Pharmacogenomics
4.1.1.3.1 Global Computational Pharmacogenomics Market Revenues, 2010 – 2018 (USD Million)
4.1.1.4 Others (Metabolomics/ Transcriptomics)
4.1.1.4.1 Global Computational Others (Metabolomics/Transcriptomics) Market Revenue, 2010 – 2018 (USD Million)
4.1.2 Disease Modelling And Simulation Applications / CADD (Computer Aided Drug Design)
4.1.2.1 Drug Discovery
4.1.2.1.1 Global Computational Drug Discovery Market Revenues, 2010 – 2018 (USD Million)
4.1.2.1.2 Target Identification
4.1.2.1.2.1 Global Computational Target Identification Market Revenues, 2010 – 2018 (USD Million)
4.1.2.1.3 Target Validation
4.1.2.1.3.1 Global Computational Target Validation Market Revenues, 2010 – 2018 (USD Million)
4.1.2.1.4 Lead Identification/Discovery
4.1.2.1.4.1 Global Computational Lead Identification Market Revenues, 2010 – 2018 (USD Million)
4.1.2.1.5 Lead Optimization
4.1.2.1.5.1 Global Computational Lead Optimization Market Revenues, 2010 – 2018 (USD Million)
4.1.2.1 Drug Development
4.1.2.1.1 Preclinical
4.1.2.1.1.1 Global Computational Preclinical Trials Market Revenues, 2010 – 2018 (USD Million)
4.1.2.1.2 Clinical Trials
4.1.2.1.2.1 Global Computational Clinical Trials Market Revenues, 2010 – 2018 (USD Million)
4.1.2.1.2.2 Phase I
4.1.2.1.2.3 Global Computational Clinical Trials Phase I Market Revenues, 2010 – 2018 (USD Million)
4.1.2.1.2.4 Phase II
4.1.2.1.2.5 Global Computational Clinical Trials Phase II Market Revenues, 2010 – 2018 (USD Million)
4.1.2.1.2.6 Phase III
4.1.2.1.2.7 Global Computational Clinical Trials Phase III Market Revenues, 2010 – 2018 (USD Million)
4.1.2.1.3 Human Body Simulation Software
4.1.2.1.3.1 Global Computational Human Simulation Software Market Revenues, 2010 – 2018 (USD Million)

Chapter 5 Global Computational Biology Market, by Tools
5.1 Overview
5.2 Database
5.2.1 Global Computational Biology Database Market Revenues, 2010 – 2018 (USD Million)
5.3 IT Infrastructure (Hardware)
5.3.1 Global Computational Biology Hardware Market Revenues, 2010 – 2018 (USD Million)
5.4 Analysis Software & Services
5.4.1 Global Computational Biology Software Market Revenues, 2010 – 2018 (USD Million)

Chapter 6 Global Computational Biology Market, by Services
6.1 Overview
6.2 In-House Computational Biology
6.2.1 Global In-House Computational Biology Market Revenues, 2010 – 2018 (USD Million)
6.3 External/Contract Computational Biology
6.3.1 Global Contract Computational Biology Market Revenues, 2010 – 2018 (USD Million)

Chapter 7 Global Computational Biology Market, by Geography
7.1 Overview
7.2 North America
7.2.1 North America Computational Biology Market Revenues, 2010 – 2018 (USD Million)
7.3 Europe
7.3.1 Europe Computational Biology Market Revenues, 2010 – 2018 (USD Million)
7.4 Asia
7.4.1 Asia Computational Biology Market Revenues, 2010 – 2018 (USD Million)
7.5 ROW
7.5.1 Row Computational Biology Market Revenues, 2010 – 2018 (USD Million)

Chapter 8 Market Share Analysis
8.1 Market Share by Key Players
8.1.1 Global Computational Biology Market Share Analysis of Key Players, 2011 (%)

Chapter 9 Recommendations
9.1 Success Strategies
9.1.1 Rigorous Research and Development (R&D) Initiatives
9.1.2 Investing in Emerging Economies
9.1.3 Investing in High-End Technologies
9.1.4 Collaborations, Mergers and Acquisitions
9.2 Barriers to be Considered
9.2.1 High Cost of Investment

Chapter 10 Company Profiles
10.1 Accelrys
10.1.1 Company Overview
10.1.2 Financial Overview
10.1.3 Product Portfolio And Services
10.1.4 Business Strategy
10.1.5 Recent Developments
10.2 Certara
10.2.1 Company Profile
10.2.2 Financial Overview
10.2.3 Product Portfolio And Services
10.2.4 Business Strategy
10.2.5 Recent Developments
10.3 Chemical Computing Group Inc.
10.3.1 Company Profile
10.3.2 Financial Overview
10.3.3 Product Portfolio
10.3.4 Business Strategy
10.3.5 Recent Developments
10.4 Compugen, Ltd
10.4.1 Company Profile
10.4.2 Financial Overview
10.4.3 Business Strategy
10.4.4 Recent Developments
10.5 Entelos
10.5.1 Company Profile
10.5.2 Financial Overview
10.5.3 Product Portfolio And Services
10.5.4 Business Strategy
10.5.5 Recent Developments
10.6 Genedata AG
10.6.1 Company Profile
10.6.2 Financial Overview
10.6.3 Product Portfolio And Services
10.6.4 Business Strategy
10.6.5 Recent Developments
10.7 Insilico Biotechnology AG
10.7.1 Company Profile
10.7.2 Financial Overview
10.7.3 Product Portfolio
10.7.4 Business Strategy
10.7.5 Recent Developments
10.8 Leadscope, Inc
10.8.1 Company Profile
10.8.2 FinancialOverview
10.8.3 Product Portfolio
10.8.4 Business Strategy
10.8.5 Recent Developments
10.9 Nimbus Discovery LLC
10.9.1 Company Profile
10.9.2 Financial Overview
10.9.3 Product Portfolio
10.9.4 Business Strategy
10.9.5 Recent Developments
10.10 RhenoviaPharma SAS
10.10.1 Company Profile
10.10.2 Financial Overview
10.10.3 Product Portfolio And Services
10.10.4 Business Startegy
10.10.5 Recent Developments
10.11 Schrodinger
10.11.1 Company Overview
10.11.2 Financial Overview
10.11.3 Product Portfolio And Services
10.11.4 Business Strategy
10.11.5 Recent Developments
10.12 Simulation Plus, Inc.
10.12.1 Company Profile
10.12.2 Financial Overview
10.12.3 Product Portfolio And Services
10.12.4 Business Strategy
10.12.5 Recent Developments

List of Tables

List of Tables

TABLE 1 Global Computational Biology Market: Snapshot (2011 & 2018)
TABLE 2 R&D Function by Expenditure (%)
TABLE 3 Global Computational Biology Market Revenues, by Segments, 2010 – 2018 (USD Million)
TABLE 4 Global Cellular Modeling and Biology Simulation Market Revenues, by Types, 2010 – 2018 (USD Million)
TABLE 5 Global Cellular Modeling and Biology Simulation Market Revenues, by Geography, 2010 – 2018 (USD Million)
TABLE 6 Global Disease Modeling and Simulation Market Revenues, by Types, 2010 - 2018 (USD Million)
TABLE 7 Global Disease Modeling and Simulation Market Revenues, by Geography, 2010 - 2018 (USD Million)
TABLE 8 Global Computational Drug Development Market Revenues, by Types, 2010 - 2018 (USD Million)
TABLE 9 Software Packages for PBPK Modeling
TABLE 10 Global Computational Biology Market Revenues, by Tools, 2010- 2018 (USD Million)
TABLE 11 Global Computational Services Market Revenues, by Services, 2010- 2018 (USD Million)
TABLE 12 Global Computational Biology Market, by Geography, 2010- 2018 (USD Million)

List of Figures

List of Figures

FIG. 1 Global Computational Biology: Market Segmentation
FIG. 2 Global Computational Biology Market, By Types, 2011 (USD Million)
FIG. 3 Average Cost to Develop one New Drug (1975 -2011) (USD Million)
FIG. 4 Trend of Rise in Failure of Phase II Clinical Trials (2006- 2012)
FIG. 5 Reasons for Failure (%) in Phase II & Phase III
FIG. 6 Porter’s Five Forces Analysis for Computational Biology Market
FIG. 7 Market Attractiveness Analysis: Global Computational Biology Market, By Geography
FIG. 8 End User Analysis: Global Computational Biology Market, 2011 & 2018 (%)
FIG. 9 Global Computational Genomics Market Revenues, 2010 – 2018 (USD Million)
FIG. 10 Global Computational Proteomics Market Revenues, 2010 – 2018 (USD Million)
FIG. 11 Global Computational Pharmacogenomics Market Revenues, 2010 – 2018 (USD Million)
FIG. 12 Global Computational Others (Metabolomics/ Transcriptomics) Market Revenue, 2010 – 2018 (USD Million)
FIG. 13 Global Computational Drug Discovery Market Revenues, 2010 – 2018 (USD Million)
FIG. 14 Global Computational Target Identification Market Revenues, 2010 – 2018 (USD Million)
FIG. 15 Global Computational Target Validation Market Revenues, 2010 – 2018 (USD Million)
FIG. 16 Global Computational Lead Identification Market Revenues, 2010 – 2018 (USD Million)
FIG. 17 Global Computational Lead Optimization Market Revenues, 2010 – 2018 (USD Million)
FIG. 18 Global Computational Preclinical Trials Market Revenues, 2010 – 2018 (USD Million)
FIG. 19 Global Computational Clinical Trials Market Revenues, 2010 – 2018 (USD Million)
FIG. 20 Global Computational Clinical Trials Phase I Market Revenues, 2010 – 2018 (USD Million)
FIG. 21 Global Computational Clinical Trials Phase II Market Revenues, 2010 – 2018 (USD Million)
FIG. 22 Global Computational Clinical Trials Phase III Market Revenues, 2010 – 2018 (USD Million)
FIG. 23 Global Computational Human Simulation Software Market Revenues, 2010 – 2012 (USD Million)
FIG. 24 Global Computational Biology Database Market Revenues, 2010 – 2018 (USD Million)
FIG. 25 Global Computational Biology Hardware Market Revenues, 2010 – 2018 (USD Million)
FIG. 26 Global Computational Biology Software Market Revenues, 2010 – 2018 (USD Million)
FIG. 27 Global In-House Computational Biology Market Revenues, 2010 – 2018 (USD Million)
FIG. 28 Global Contract Computational Biology Market Revenues, 2010 – 2018 (USD Million)
FIG. 29 North America Computational Biology Market Revenues, 2010 – 2018 (USD Million)
FIG. 30 Europe Computational Biology Market Revenues, 2010 – 2018 (USD Million)
FIG. 31 Asia Computational Biology Market Revenue, 2010 – 2018 (USD Million)
FIG. 32 Row Computational Biology Market Revenues, 2010 – 2018 (USD Million)
FIG. 33 Global Computational Biology Market Share Analysis Of Key Players, 2011 (%)
FIG. 34 Annual Revenues: Accelrys, 2009 - 2011 (USD Million)
FIG. 35 Annual Revenue: Compugen, 2010 – 2012 (USD Million)
FIG. 36 Annual Revenues: Simulation Plus, Inc., 2010 – 2012 (USD Million)

Upcoming Reports:

Skincare Market - Global Industry Size, Market Share, Trends, Analysis, And Forecasts 2012 - 2018
By - Transparency Market Research
Technological advancement in the skin care market combined with development of innovative products providing effective results and ease of use are contributing to the growth of this industry. The increasing demand for anti-ageing products and growing concern for the use of natural and organic skin care products are the major factors driving the skin care industry.  The growing consumer concern for the use of natural and organic skin care products is encouraging new manufacturers to enter the market. Intense competition can pose a serious challenge to the growth of the...
Laboratory Filtration Equipment Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast 2014 - 2020
By - Transparency Market Research
Filtration is a necessary process step in almost all kind of laboratories related to environmental, chemistry, and life sciences applications. It is the most common technique used either to purify or concentrate samples in the laboratory. The basic equipment used for filtration process has evolved over the years and market is witnessing modern, sophisticated filtration methods capable of ultra-purifying the sample which could not have been possible with conventional methods. Laboratory filtration equipment helps an analyst in sample clarification before analysis, mobile phase filtration,...
Passive and Active Remote Sensing Technology Market - Global Industry Size, Share, Trends, Analysis, and Forecast, 2012 - 2018
By - Transparency Market Research
Remote sensing technology is the gathering of information about an object or incident without making any contact with it. In modern usage, the term usually refers to the use of aerial sensor technologies for the detection of objects in the atmosphere and on the earth.  Remote sensing technology is classified into two major types - active remote sensing and passive remote sensing. Passive remote sensors detect the natural radiation emitted or reflected by an object or surrounding areas while the active sensor technology emits energy to scan the object and areas to...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Private Schools Have Higher Male Teaching Staff Than State Schools: Report
Oct 22, 2014  
Private and state education has always been a matter of debate across the UK. A recent study has shown that when it comes to teaching employment options, the difference between state-run and private education in terms of gender balance is absolutely clear.  A report by the Independent Schools Council (ISC) shows that while women dominate both the education medium, the number of...
Abbots First Australian Renewable Energy Deal Rejected
Oct 22, 2014  
The Abbot government’s initial deal for a renewable energy plan has been immediately rejected by the clean energy industry and Labor. The negotiations are about a bipartisan agreement regarding the future of the Australian renewable energy target. The Labor party rejected the first plan as being a job-killer before it was even announced. The plan, they said, would protect solar...
Chemical Production in Europe Flatlines in First Seven Months of 2014
Oct 21, 2014  
The recently published report by European Chemical Industry Council (Cefic) shows overall chemical production in Europe has flatlined in first seven months of this year. Though the initial four months showed a positive trend, the production volumes dropped in July 2014 and in the following months as well. The contraction in output in the three consecutive months has nullified the upward trend...
Actavis to Compete for Omega Pharma
Oct 20, 2014  
Actavic Plc has declared that it will become one of the bidders for the Omega Pharma NV deal, as the United States based drug maker keeps searching for more takeovers. Actavis will be competing against Boehringer Ingelheim GmbH, Sanofi and Perrigi Co. for Omega Pharma. Actavis places themselves as a potential suitor along with quarry in a multitude of potential pharma combinations....
Sale of iPhone Fuels UKs s
Oct 20, 2014  
With the sale of Apple Inc.’s latest smartphone, consumer expenditure on electronics has registered a three-year high this September. The new iPhone 6 and iPhone 6 Plus were launched in the U.K. on September 19 and buyers from across the country raced to purchase the newest smartphone. Both these smartphones are so far the fastest selling Apple products with a sale of over 10 million...